WO2006111517A1 - Derives de benzimidazole et leur utilisation dans la modulation du complexe recepteur gabaa - Google Patents

Derives de benzimidazole et leur utilisation dans la modulation du complexe recepteur gabaa Download PDF

Info

Publication number
WO2006111517A1
WO2006111517A1 PCT/EP2006/061621 EP2006061621W WO2006111517A1 WO 2006111517 A1 WO2006111517 A1 WO 2006111517A1 EP 2006061621 W EP2006061621 W EP 2006061621W WO 2006111517 A1 WO2006111517 A1 WO 2006111517A1
Authority
WO
WIPO (PCT)
Prior art keywords
piperazin
phenyl
benzoimidazol
disorder
ethanone
Prior art date
Application number
PCT/EP2006/061621
Other languages
English (en)
Inventor
Lene Teuber
Janus S. Larsen
Philip K. Ahring
Elsebet Østergaard NIELSEN
Naheed Mirza
Original Assignee
Neurosearch A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch A/S filed Critical Neurosearch A/S
Priority to US11/918,681 priority Critical patent/US20090062304A1/en
Priority to EP06743313A priority patent/EP1874735A1/fr
Publication of WO2006111517A1 publication Critical patent/WO2006111517A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • This invention relates to novel benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith.
  • the compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAA receptor complex, and in particular for combating anxiety and related diseases.
  • the modulatory sites on the GABA A receptor complex are the targets for anxiolytic drugs, such as the classical anxiolytic benzodiazepines. However, they are associated with a number of undesirable features.
  • each receptor is a pentameric complex comprising subunits drawn from ⁇ -i- ⁇ , ⁇ i- 3 , ⁇ i- 3 , ⁇ , ⁇ , and ⁇ subunit isoforms.
  • the classical anxiolytic benzodiazepines show no subtype selectivity. It has been suggested that one of the key elements in the disadvantages of the classical benzodiazepanes (such as sedation, dependency, and cognitive impairment) is related to the ⁇ 1 subunit of the GABAA receptors.
  • compounds with selectivity for the ⁇ 2 and/or ⁇ 3 subunits over the ⁇ 1 subunit are expected to have an improved side effect profile.
  • optimised pharmacological profile Furthermore, there is a strong need to find effective compounds without unwanted side effects associated with older compounds.
  • the invention provides a compound of Formula I:
  • R a , n and R b are defined as below.
  • the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of a compound of the invention, or an N- oxide thereof, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
  • the invention provides the use of a compound of the invention, or an N-oxide thereof, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of the GABA A receptor complex in the central nervous system.
  • the invention relates to a method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to modulation of the GABA A receptor complex in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound of the invention, or an N- oxide thereof, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof.
  • R a represents an alkyl group; which alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, hydroxy, R'R"N-, cyano, nitro, cycloalkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, formyl, alkylcarbonyl, alkoxycarbonyl, alkoxyalkylcarbonyl or R'R"N-carbonyl-; wherein R' and R" independent of each other are hydrogen or alkyl; n is O or 1 ; R b represents hydrogen or alkyl.
  • R a represents an alkyl group; which alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, hydroxy, R'R"N-, cyano, nitro, cycloalkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, formyl, alkylcarbonyl, alkoxycarbonyl, alkoxyalkylcarbonyl or R'R"N- carbonyl-; wherein R' and R" independent of each other are hydrogen or alkyl.
  • R a represents alkyl. In a special embodiment, R a represents methyl or isopropyl.
  • R a represents alkyl substituted with one or more halo, such as perhaloalkyl. In a special embodiment, R a represents trifluoromethyl.
  • R a represents alkyl substituted with cyano, hydroxyl, alkoxy, alkenyloxy, alkynyloxy, alkoxycarbonyl, or R'R"N-carbonyk In a further embodiment, R a represents alkyl substituted with cyano, hydroxyl, alkoxy, alkenyloxy, alkoxycarbonyl, or R'R"N-carbonyk
  • R a represents cyanoalkyl, such as cyanomethyl.
  • R a represents hydroxyalkyl, such as 1- hydroxyethyl.
  • R a represents alkyl substituted with alkoxy, such as 1- alkoxyethyl.
  • R a represents methoxyalkyl, such as methoxyethyl, such as 1-methoxyethyl.
  • R a represents ethoxyalkyl, such as ethoxyethyl, such as 1-ethoxyethyl.
  • R a represents propoxyalkyl, such as propoxyethyl, such as 1-propoxyethyl, in particular 1-isopropoxyethyl.
  • R a represents alkyl substituted with alkynyloxy, such as prop-2-ynyloxy. In a special embodiment, R a represents 1-prop-2-ynyloxy-ethyl. In a still further embodiment, R a represents alkyl substituted with alkoxycarbonyl, such as methoxycarbonylalkyl. In a special embodiment, R a represents methoxycarbonylmethyl.
  • R a represents alkyl substituted with R'R"N-carbonyk
  • R' represents hydrogen or methyl
  • R" represents hydrogen or methyl.
  • R a represents aminocarbonylmethyl, methylaminocarbonylmethyl or dimethylaminocarbonylmethyl.
  • n is 0.
  • n is 1.
  • R b represents alkyl, such as methyl.
  • halo represents fluoro, chloro, bromo or iodo.
  • an alkyl group designates a univalent saturated, straight or branched hydrocarbon chain.
  • the hydrocarbon chain preferably contain of from one to six carbon atoms (Ci -6 -alkyl), including pentyl, isopentyl, neopentyl, tertiary pentyl, hexyl and isohexyl.
  • alkyl represents a Ci-4-alkyl group, including butyl, isobutyl, secondary butyl, and tertiary butyl.
  • alkyl represents a d- 3 -alkyl group, which may in particular be methyl, ethyl, propyl or isopropyl.
  • an alkenyl group designates a carbon chain containing one or more double bonds, including di-enes, tri-enes and poly-enes.
  • the alkenyl group of the invention comprises of from two to six carbon atoms (C2- 6 -alkenyl), including at least one double bond.
  • the alkenyl group of the invention is ethenyl; 1- or 2-propenyl; 1-, 2- or 3- butenyl, or 1 ,3-butadienyl; 1-, 2-, 3-, 4- or 5-hexenyl, or 1 ,3-hexadienyl, or 1 ,3,5- hexatrienyl.
  • an alkynyl group designates a carbon chain containing one or more triple bonds, including di-ynes, tri-ynes and poly-ynes.
  • the alkynyl group of the invention comprises of from two to six carbon atoms (C 2-6 -alkynyl), including at least one triple bond.
  • the alkynyl group of the invention is ethynyl; 1-, or 2-propynyl; 1-, 2-, or 3- butynyl, or 1 ,3-butadiynyl; 1-, 2-, 3-, 4-pentynyl, or 1 ,3-pentadiynyl; 1-, 2-, 3-, 4-, or 5- henynyl, or 1 ,3-hexadiynyl or 1 ,3,5-hexatriynyl.
  • a cycloalkyl group designates a cyclic alkyl group, preferably containing of from three to seven carbon atoms (C 3 - 7 -cycloalkyl), including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • Alkoxy means O-alkyl, wherein alkyl is as defined above.
  • Alkoxyalkyl means alkoxy as above and alkyl as above, meaning for example, methoxymethyl.
  • the chemical compound of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the chemical compound of the invention.
  • Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydro- chloride, the hydrobromide, the nitrate, the perchlorate, the phosphate, the sulphate, the formate, the acetate, the aconate, the ascorbate, the benzenesulphonate, the benzoate, the cinnamate, the citrate, the embonate, the enantate, the fumarate, the glutamate, the glycolate, the lactate, the maleate, the malonate, the mandelate, the methanesulphonate, the naphthalene-2-sulphonate derived, the phthalate, the sali- cylate, the sorbate, the stearate, the succinate, the tartrate, the toluene-p-sulphonate, and the like.
  • Such salts may be formed by procedures well known and described in the art.
  • acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt.
  • Examples of pharmaceutically acceptable cationic salts of a chemical compound of the invention include, without limitation, the sodium, the potassium, the calcium, the magnesium, the zinc, the aluminium, the lithium, the choline, the lysinium, and the ammonium salt, and the like, of a chemical compound of the invention containing an anionic group.
  • Such cationic salts may be formed by procedures well known and described in the art.
  • onium salts of N-containing compounds are also contemplated as pharmaceutically acceptable salts.
  • Preferred “onium salts” include the alkyl-onium salts, the cycloalkyl-onium salts, and the cycloalkylalkyl-onium salts.
  • pre- or prodrug forms of the chemical compound of the invention include examples of suitable prodrugs of the substances according to the invention include compounds modified at one or more reactive or derivatizable groups of the parent compound. Of particular interest are compounds modified at a carboxyl group, a hydroxyl group, or an amino group. Examples of suitable derivatives are esters or amides.
  • the chemical compound of the invention may be provided in dissoluble or indissoluble forms together with a pharmaceutically acceptable solvent such as water, ethanol, and the like.
  • Dissoluble forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, the dissoluble forms are considered equivalent to indissoluble forms for the purposes of this invention.
  • the compounds of the present invention may contain one or more chiral centres and that such compounds may exist in different stereoisomeric forms - including enantiomers, diastereomers and cis-trans-isomers.
  • the invention includes all such isomers and any mixtures thereof including racemic mixtures.
  • Optical active compounds can also be prepared from optical active starting materials.
  • an N-oxide designates an oxide derivative of a nitrogen containing compound, e.g. N-containing heterocyclic compounds capable of forming such N-oxides, and compounds holding one or more amino groups.
  • the N-oxide of a compound containing a pyridyl may be the 1-oxy-pyridin-2, -3 or -4-yl derivative.
  • N-oxides of the compounds of the invention may be prepared by oxidation of the corresponding nitrogen base using a conventional oxidizing agent such as hydrogen peroxide in the presence of an acid such as acetic acid at an elevated temperature, or by reaction with a peracid such as peracetic acid in a suitable solvent, e.g. dichloromethane, ethyl acetate or methyl acetate, or in chloroform or dichloromethane with 3-chloroperoxybenzoic acid.
  • a suitable solvent e.g. dichloromethane, ethyl acetate or methyl acetate, or in chloroform or dichloromethane with 3-chloroperoxybenzoic acid.
  • the compounds of the invention may be used in their labelled or unlabelled form.
  • the labelled compound has one or more atoms replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • the labelling will allow easy quantitative detection of said compound.
  • the labelled compounds of the invention may be useful as diagnostic tools, radio tracers, or monitoring agents in various diagnostic methods, and for in vivo receptor imaging.
  • the labelled isomer of the invention preferably contains at least one radionuclide as a label.
  • Positron emitting radionuclides are all candidates for usage.
  • the radionuclide is preferably selected from 2 H (deuterium),
  • the physical method for detecting the labelled isomer of the present invention may be selected from Position Emission Tomography (PET), Single Photon Imaging
  • SPECT Computed Tomography
  • MRS Magnetic Resonance Spectroscopy
  • MRI Magnetic Resonance Imaging
  • CAT Computed Axial X-ray Tomography
  • the chemical compounds of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples.
  • the starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals.
  • one compound of the invention can be converted to another compound of the invention using conventional methods.
  • the end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.
  • the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like.
  • pharmaceutically acceptable solvents such as water, ethanol and the like.
  • the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.
  • Compounds of the invention are capable of modulating the GABA A receptor complex. They may be tested for their ability to bind to the GABAA receptor complex, including specific subunits thereof.
  • the compounds of the present invention being ligands for the benzodiazepine binding site on GABAA receptors, are therefore of use in the treatment and/or prevention of a variety of disorders of the central nervous system.
  • the compounds of the invention are considered useful for the treatment, prevention or alleviation of a disease, disorder or condition responsive to modulation of the GABAA receptor complex in the central nervous system.
  • the compounds of the invention are considered useful for the treatment, prevention or alleviation of
  • anxiety disorders such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, animal and other phobias including social phobias, obsessive-compulsive disorder, and generalized or substance-induced anxiety disorder;
  • convulsive disorders for example epilepsy, seizures, convulsions, or febrile convulsions in children;
  • depressive or bipolar disorders for example depression, single-episode or recurrent major depressive disorder, dysthymic disorder, bipolar disorder, bipolar I and bipolar Il manic disorders, and cyclothymic disorder, • psychotic disorders, including schizophrenia;
  • emesis including acute, delayed and anticipatory emesis, in particular emesis induced by chemotherapy or radiation;
  • eating disorders including anorexia nervosa and bulimia nervosa;
  • neuralgia e.g. trigeminal neuralgia
  • muscle spasm or spasticity e.g. in paraplegic patients
  • the compounds of the invention are considered useful for the treatment, prevention or alleviation of anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, animal and other phobias including social phobias, obsessive-compulsive disorder, and generalized or substance-induced anxiety disorder;
  • anxiety disorders such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, animal and other phobias including social phobias, obsessive-compulsive disorder, and generalized or substance-induced anxiety disorder;
  • the compounds of the invention may be useful as radioligands in assays for detecting compounds capable of binding to the human GABA A receptor.
  • a suitable dosage of the active pharmaceutical ingredient (API) is within the range of from about 0.1 to about 1000 mg API per day, more preferred of from about 10 to about 500 mg API per day, most preferred of from about 30 to about 100 mg API per day, dependent, however, upon the exact mode of administration, the form in which it is administered, the indication considered, the subject and in particular the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
  • Preferred compounds of the invention show a biological activity in the sub- micromolar and micromolar range, i.e. of from below 1 to about 100 ⁇ M.
  • the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the chemical compound of the invention. While a chemical compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
  • the invention provides pharmaceutical compositions comprising the chemical compound of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers, and, optionally, other therapeutic and/or prophylactic ingredients, known and used in the art.
  • the carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.
  • compositions of the invention may be those suitable for oral, rectal, bronchial, nasal, pulmonal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral (including cutaneous, subcutaneous, intramuscular, intraperitoneal, intravenous, intraarterial, intracerebral, intraocular injection or infusion) administration, or those in a form suitable for administration by inhalation or insufflation, including powders and liquid aerosol administration, or by sustained release systems.
  • sustained release systems include semipermeable matrices of solid hydrophobic polymers containing the compound of the invention, which matrices may be in form of shaped articles, e.g. films or microcapsules.
  • compositions and unit dosages thereof may thus be placed into the form of pharmaceutical compositions and unit dosages thereof.
  • forms include solids, and in particular tablets, filled capsules, powder and pellet forms, and liquids, in particular aqueous or non-aqueous solutions, suspensions, emulsions, elixirs, and capsules filled with the same, all for oral use, suppositories for rectal administration, and sterile injectable solutions for parenteral use.
  • Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • the chemical compound of the present invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a chemical compound of the invention or a pharmaceutically acceptable salt of a chemical compound of the invention.
  • pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from five or ten to about seventy percent of the active compound.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
  • a low melting wax such as a mixture of fatty acid glyceride or cocoa butter
  • the active component is dispersed homogeneously therein, as by stirring.
  • the molten homogenous mixture is then poured into convenient sized moulds, allowed to cool, and thereby to solidify.
  • compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Liquid preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions.
  • parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
  • the chemical compound according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening agents, as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents. Also included are solid form preparations, intended for conversion shortly before use to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. In addition to the active component such preparations may comprise colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the chemical compound of the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
  • compositions suitable for topical administration in the mouth include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • compositions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
  • the compositions may be provided in single or multi-dose form.
  • Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoro- methane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoro- methane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • CFC chlorofluorocarbon
  • the aerosol may conveniently also contain a surfactant such as lecithin.
  • the dose of drug may be controlled by
  • the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
  • a powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
  • PVP polyvinylpyrrolidone
  • the powder carrier will form a gel in the nasal cavity.
  • the powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.
  • the compound In compositions intended for administration to the respiratory tract, including intranasal compositions, the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.
  • compositions adapted to give sustained release of the active ingredient may be employed.
  • the pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • Tablets or capsules for oral administration and liquids for intravenous administration and continuous infusion are preferred compositions.
  • a therapeutically effective dose refers to that amount of active ingredient, which ameliorates the symptoms or condition.
  • Therapeutic efficacy and toxicity e.g. ED 50 and LD 50
  • ED 50 and LD 50 may be determined by standard pharmacological procedures in cell cultures or experimental animals.
  • the dose ratio between therapeutic and toxic effects is the therapeutic index and may be expressed by the ratio LD 50 ZED 50 .
  • Pharmaceutical compositions exhibiting large therapeutic indexes are preferred.
  • the dose administered must of course be carefully adjusted to the age, weight and condition of the individual being treated, as well as the route of administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner.
  • compositions containing of from about 0.1 to about 500 mg of active ingredient per individual dose, preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.
  • the active ingredient may be administered in one or several doses per day.
  • a satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1 ⁇ g/kg i.v. and 1 ⁇ g/kg p.o.
  • the upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o.
  • Preferred ranges are from about 0.1 ⁇ g/kg to about 10 mg/kg/day i.v., and from about 1 ⁇ g/kg to about 100 mg/kg/day p.o.
  • the invention provides a method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to modulation of the GABA A receptor complex in the central nervous system, and which method comprises administering to such a living animal body, including a human, in need thereof an effective amount of a chemical compound of the invention.
  • suitable dosage ranges are 0.1 to 1000 milligrams daily, 10-500 milligrams daily, and especially 30-100 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
  • N-[3-(4-Acetyl-piperazin-1-yl)-phenyl]-formamide (2) A mixture of 1 (5.4g, 24.7mmol) and formic acid (50ml) was stirred at reflux for 45min. Formic acid was removed in vacuo, and the residue was partitioned between saturated, aqueous sodium carbonate and ethyl acetate. The organic layer was dried over sodium sulfate and evaporated to leave 2 (5.3g, 87%).
  • R Ac 19
  • R CH 2 CN 15
  • R CF 3 20
  • R CH 2 CONH 2 16
  • R OMe 21
  • R CH 2 CONHMe 17
  • R OCF 3 22
  • R CH 2 CONMe 2
  • the GABA recognition site and the benzodiazepine modulatory unit can selectively be labelled with 3 H-flunitrazepam.
  • Cerebral cortex from male Wistar rats (150-200 g) is homogenised for 5-10 sec in 20 ml Tris-HCI (30 mM, pH 7.4) using an Ultra-Turrax homogeniser. The suspension is centrifuged at 27,000 x g for 15 min and the pellet is washed three times with buffer (centrifuged at 27,000 x g for 10 min). The washed pellet is homogenized in 20 ml of buffer and incubated on a water bath (37 0 C) for 30 min to remove endogenous GABA and then centrifuged for 10 min at 27,000 x g. The pellet is then homogenized in buffer and cen- trifuged for 10 min at 27,000 x g. The final pellet is resuspended in 30 ml buffer and the preparation is frozen and stored at -2O 0 C.
  • the membrane preparation is thawed and centrifuged at 2 0 C for 10 min at 27,000 x g.
  • the pellet is washed twice with 20 ml 50 mM Tris-citrate, pH 7.1 using an Ultra- Turrax homogeniser and centrifuged for 10 min at 27,000 x g.
  • the final pellet is resuspended in 50 mM Tris-citrate, pH 7.1 (500 ml buffer per g of original tissue), and then used for binding assays.
  • Aliquots of 0.5 ml tissue are added to 25 ⁇ l of test solution and 25 ⁇ l Of 3 H-FNM (1 nM, final concentration), mixed and incubated for 40 min at 2 0 C.
  • Non-specific binding is determined using Clonazepam (1 ⁇ M, final concentration). After incubation the samples are added 5 ml of ice-cold buffer and poured directly onto Whatman GF/C glass fibre filters under suction and immediately washed with 5 ml ice-cold buffer. The amount of radioactivity on the filters is determined by conventional liquid scintillation counting. Specific binding is total binding minus non-specific binding.
  • IC 5O the concentration ( ⁇ M) of the test substance which inhibits the specific binding Of 3 H-FNM by 50%.
  • IC 50 (applied test substance concentration, ⁇ M) x
  • C 0 is specific binding in control assays
  • C x is the specific binding in the test assay. (The calculations assume normal mass-action kinetics).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux dérivés de benzimidazole, des compositions pharmaceutiques contenant ces composés ainsi que des méthodes de traitement utilisant ces compositions pharmaceutiques. Les composés selon l'invention sont utiles pour traiter les maladies et les troubles du système nerveux central, qui sont sensibles à la modulation du complexe récepteur GABAA, et notamment pour combattre l'anxieté et les maladies associées.
PCT/EP2006/061621 2005-04-19 2006-04-18 Derives de benzimidazole et leur utilisation dans la modulation du complexe recepteur gabaa WO2006111517A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/918,681 US20090062304A1 (en) 2005-04-19 2006-04-18 Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex
EP06743313A EP1874735A1 (fr) 2005-04-19 2006-04-18 Derives de benzimidazole et leur utilisation dans la modulation du complexe recepteur gabaa

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200500566 2005-04-19
DKPA200500566 2005-04-19
US67287805P 2005-04-20 2005-04-20
US60/672,878 2005-04-20

Publications (1)

Publication Number Publication Date
WO2006111517A1 true WO2006111517A1 (fr) 2006-10-26

Family

ID=36699100

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/061621 WO2006111517A1 (fr) 2005-04-19 2006-04-18 Derives de benzimidazole et leur utilisation dans la modulation du complexe recepteur gabaa

Country Status (2)

Country Link
EP (1) EP1874735A1 (fr)
WO (1) WO2006111517A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017651A1 (fr) * 1996-10-21 1998-04-30 Neurosearch A/S Composes 1-phenyl-benzimidazole et leur utilisation comme modulateurs du recepteur baga-¿a?
WO2000078728A1 (fr) * 1999-06-22 2000-12-28 Neurosearch A/S Nouveaux derives de benzimidazole et compositions pharmaceutiques comprenant ces composes
WO2002050057A1 (fr) * 2000-12-20 2002-06-27 Neurosearch A/S Nouveaux derives de benzimidazole pour le traitement de troubles induits par gaba-alpha
WO2004087690A2 (fr) * 2003-04-03 2004-10-14 Neurosearch A/S Derives de benzimidazole et leur utilisation pour moduler le complexe du recepteur gabaa
WO2004089912A1 (fr) * 2003-04-10 2004-10-21 Neurosearch A/S Nouveau derives de benzimidazole et compositions pharmaceutiques comprenant ces composes
WO2005040131A1 (fr) * 2003-10-23 2005-05-06 Akzo Nobel N.V. Derives de benzimidazole 1,5,7-trisubstitutes et leur utilisation pour la modulation du complexe recepteur gabaa

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017651A1 (fr) * 1996-10-21 1998-04-30 Neurosearch A/S Composes 1-phenyl-benzimidazole et leur utilisation comme modulateurs du recepteur baga-¿a?
WO2000078728A1 (fr) * 1999-06-22 2000-12-28 Neurosearch A/S Nouveaux derives de benzimidazole et compositions pharmaceutiques comprenant ces composes
WO2002050057A1 (fr) * 2000-12-20 2002-06-27 Neurosearch A/S Nouveaux derives de benzimidazole pour le traitement de troubles induits par gaba-alpha
WO2004087690A2 (fr) * 2003-04-03 2004-10-14 Neurosearch A/S Derives de benzimidazole et leur utilisation pour moduler le complexe du recepteur gabaa
WO2004089912A1 (fr) * 2003-04-10 2004-10-21 Neurosearch A/S Nouveau derives de benzimidazole et compositions pharmaceutiques comprenant ces composes
WO2005040131A1 (fr) * 2003-10-23 2005-05-06 Akzo Nobel N.V. Derives de benzimidazole 1,5,7-trisubstitutes et leur utilisation pour la modulation du complexe recepteur gabaa

Also Published As

Publication number Publication date
EP1874735A1 (fr) 2008-01-09

Similar Documents

Publication Publication Date Title
US7939556B2 (en) Imidazole derivatives and their use for modulating the GABAA receptor complex
US7858649B2 (en) Imidazole derivatives and their use for modulating the GABAA receptor complex
US7923464B2 (en) Benzimidazole derivatives and their use for modulating the GABAA receptor complex
EP1877052B1 (fr) Derives du benzimidazole et leurs utilisations pour moduler le complexe du recepteur gabaa
US20060069135A1 (en) Benzimidazole derivatives and their use for modulating the gaba-a receptor complex
WO2010055133A1 (fr) Dérivés de benzimidazole et leur utilisation dans la modulation du complexe du récepteur gabaa
EP1613312B1 (fr) Derives de benzimidazole et leur utilisation dans la modulation du complexe du recepteur gaba a
EP2365971B1 (fr) Dérivés de benzimidazole et leur utilisation dans la modulation du complexe du recépteur gabaa
US7776900B2 (en) Benzimidazole derivatives and their use for modulating the GABAAreceptor complex
EP1874735A1 (fr) Derives de benzimidazole et leur utilisation dans la modulation du complexe recepteur gabaa
US20090062304A1 (en) Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex
EP1615896B1 (fr) Nouveau derives de benzimidazole et compositions pharmaceutiques comprenant ces composes
US20080312303A1 (en) Imidazole Derivatives and Their Use for Modulating the Gabaa Receptor Complex
Larsen et al. Benzimidazole derivatives and their use for modulating the GABAA receptor complex
WO2010055131A1 (fr) Dérivés de benzimidazole et leur utilisation pour la modulation du complexe du récepteur gabaa

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006743313

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11918681

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006743313

Country of ref document: EP